替吉奥临床应用新进展

New Progress in Clinical Application of Teggio

替吉奥(S-1)属于一种氟尿嘧啶衍生物,为口服抗癌剂,其主要成分为替加氟及吉美嘧啶、奥替拉西两种生化调节剂。其中生化调节剂均为氟尿嘧啶的增效减毒改良制剂。现临床上多采用S-1治疗多种消化道肿瘤和部分晚期转移癌,此外在临床应用中联合替吉奥的不同化疗方案也获得了满意疗效,但针对胃癌、结直肠癌、胰腺癌、非小细胞肺癌、乳腺癌等的疗效和方案还需进一步完善。本文旨在探讨替吉奥在胃癌、结直肠癌、胰腺癌、非小细胞肺癌、乳腺癌等治疗中的新进展。

Tegafur Gimeracil Oteracil Potassium Capsule(S-1)belongs to a fluorouracil derivative and is an oral anticancer agent.Its main components are tegafon,gimilacil and oetirash,two biochemical modifiers.Among them,the biochemical regulator is an improved preparation of fluorouracil.In clinic,S-1 is used to treat many kinds of digestive tract tumors and some advanced metastatic cancers.In addition,the different chemotherapy regimens of combination with Tegafur Gimeracil Oteracil Potassium Capsule have also achieved satisfactory results in clinical application,but the therapeutic effects and plans for gastric cancer,colorectal cancer,pancreatic cancer,non-small cell lung cancer and breast cancer need to be further improved.This article aims to explore the new progress of teggio in the treatment of gastric cancer,colorectal cancer,pancreatic cancer,non-small cell lung cancer and breast cancer.